BBA
MCRB icon

Baker Bros. Advisors’s Seres Therapeutics MCRB Stock Holding History

Baker Bros. Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6,250
Closed -$1.41M – 123
2017
Q2 		$1.41M Hold
6,250
– – 0.01% 95
2017
Q1 		$1.41M Hold
6,250
– – 0.01% 95
2016
Q4 		$1.24M Hold
6,250
– – 0.01% 103
2016
Q3 		$1.54M Hold
6,250
– – 0.01% 103
2016
Q2 		$3.63M Hold
6,250
– – 0.04% 78
2016
Q1 		$3.32M Hold
6,250
– – 0.04% 84
2015
Q4 		$4.39M Hold
6,250
– – 0.04% 83
2015
Q3 		$3.71M Hold
6,250
– – 0.03% 85
2015
Q2 		$5.19M Buy
+6,250
New +$5.45M 0.05% 79

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Baker Bros. Advisors's MCRB Position: Q3 2017 in Review

Baker Bros. Advisors sold out of Seres Therapeutics (MCRB) in Q3 2017, closing a stake of 6,250 shares — an estimated $1.41M sold.

Baker Bros. Advisors first reported a position in MCRB in Q2 2015 and held it in 9 quarters. The position peaked at $5.19M in Q2 2015. 80 funds tracked by Wall St. Rank hold MCRB as of Q3 2017.

  • Baker Bros. Advisors reported no remaining Seres Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Baker Bros. Advisors sold 6,250 Seres Therapeutics shares in Q3 2017, an estimated $1.41M.
  • Baker Bros. Advisors first reported a position in Seres Therapeutics in Q2 2015 and held it in 9 quarters.
  • Baker Bros. Advisors's Seres Therapeutics position peaked at $5.19M in Q2 2015.
  • 80 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2017.

Based on Baker Bros. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.